ORCL Faces Battle Over PSFT
Stocks
settled into a trading range today, finishing off flat. New
home sales slipped 1.7% to a seasonally adjusted 1.106 million from previous
forecasts of 1.125 million. Weekly Initial claims rose by another 10K,
strengthening the argument of a jobless recovery. According to the World Health
Organization, scientists are just weeks away from a human bird flu vaccine. The
dollar peaked at a one-month high against the euro at $1.2427 on a possible ECB
rate cut. The Justice Department will block Oracle’s bid to acquire
PeopleSoft
(
PSFT |
Quote |
Chart |
News |
PowerRating) because it is “anti-competitive, pure, and simple.”
Larry Ellison said he would sue the government if they tried to block the
acquisition. PSFT is down 3% today.
Genentech
(
DNA |
Quote |
Chart |
News |
PowerRating) received early
approval from the FDA for Avastin, used as a first-line treatment for metastatic
colorectal cancer. Avastin works by preventing the formation of new blood
vessels, potentially extending the life of a patient by 5 months. The drug is
expected to cost $400 a month with annual sales exceeding $1 billion. Darden
Restaurants
(
DRI |
Quote |
Chart |
News |
PowerRating) upped its quarterly forecasts with earnings to reach
45 cents. Its Olive Garden same-store sales have risen 4% and a turnaround in
its struggling Red Lobster chain is in the works. The news was followed by three
upgrades from Wachovia, Thomas Weisel and Raymond James. Retailer Kohls
(
KSS |
Quote |
Chart |
News |
PowerRating)
reported fourth-quarter earnings that fell to $246.8 million with net sales
rising to $3.6 billion. Same-store sales fell by 2.1%.
| Dow | -21.48 |
10580.14 |
| S&P 500 |
+1.24 | 1144.91 |
| Nasdaq | +9.60 | 2032.58 |
The day’s leading sectors were
Biotechs
(
BTK.X |
Quote |
Chart |
News |
PowerRating) +1.93%, Disk Drives
(
DDX.X |
Quote |
Chart |
News |
PowerRating) +1.53%,
Hardware
(
GHA.X |
Quote |
Chart |
News |
PowerRating) +1.46%, and Semis
(
SOX.X |
Quote |
Chart |
News |
PowerRating) +1.46%.
Weak today were Chemicals
(
CEX.X |
Quote |
Chart |
News |
PowerRating) -0.63%, and Pharmaceuticals
(
DRG.X |
Quote |
Chart |
News |
PowerRating) -0.16%,
Economic news releases included
initial claims that rose 10k to 350k. Durable orders fell by 1.8%. New home
sales were lower-than-expected at 1.106 million units and the Help-Wanted index
fell a point to 38.
10-year Notes were -65
at 114 300
The dollar
was +0.47 at 87.79
Gold was +4.00 at 395.90
Crude oil was -0.21 at
35.47
The euro
was -0.60 at 124.31
Volume was 1,368,000,000
on the NYSE, and 1,722,000,000 on the Nasdaq.
Market breadth was positive.
| NYSE | Issues | |
| Advancing | 1783 | Up Vol 327 |
| Declining | 1298 | Down Vol 242 |
| Ratio | 1.40 | 1.34 |
| Nasdaq | ||
| Advancing | 1616 | Up Vol 534 |
| Declining | 1336 | Dow Vol 222 |
| Ratio | 2.22 | 2.41 |
Top Dow stocks were:
Hewlett Packard [HPQ|HPQ],
+1.82% at 23.17, Disney
(
DIS |
Quote |
Chart |
News |
PowerRating), +1.60% at 26.78, Caterpillar [CAT|CAT]
+1.09% at 78.06, and Home Depot [HD|HD],
+0.92% at 28.11.
Stocks in the news:
J.C. Penney
(
JCP |
Quote |
Chart |
News |
PowerRating) reported a loss
of $928 million on revenue of $17.79 billion with earnings from continuing
operations up 43%. For the first quarter, JCP expects earnings from continuing
operation to exceed 9 cents a share. Excluding charges, JCP earned 83 cents a
share, ahead of analysts’ estimates.
Pension fund Calpers stated that it had lost
confidence in Disney’s
(
DIS |
Quote |
Chart |
News |
PowerRating) Eisner’s leadership. Its holdings in
Disney have dropped 23% over the last 5 years.
Men’s Wearhouse
(
MW |
Quote |
Chart |
News |
PowerRating) reported
earnings of $20.8 million on revenue of $422.7 million The company expects
first-quarter earnings to be $1.63 a share.
Calpine
(
CPN |
Quote |
Chart |
News |
PowerRating) reported
fourth-quarter earnings of $119.6 million from a loss of $25.2 million with
revenue at $1.92 billion a year ago.
Decode Genetics
(
DCGN |
Quote |
Chart |
News |
PowerRating) rose on
the news of its drug development alliance with Merck
(
MRK |
Quote |
Chart |
News |
PowerRating). DCGN will
receive royalties on sales of drugs and diagnostics with clinical development
costs to be shared.